Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$2.92B, compared with -$2.7B a year earlier.
Context
- Retained earnings amounted to 295.0% of total assets at the end of Q3 FY2026, down 3.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (2.78B) USD
- Year-over-year change
- -16.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.78B) | -16.4% |
| FY2024 | 2024-12-31 | (2.38B) | -18.5% |
| FY2023 | 2023-12-31 | (2.01B) | -28.3% |
| FY2022 | 2022-12-31 | (1.57B) | -33.8% |
| FY2021 | 2021-12-31 | (1.17B) | — |
Retained Earnings vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -8.2% is the 4th highest of 11, against a peer median of -10.9%.
- Retained earnings amounts to 295.0% of total assets for IOVA, versus a peer median of 271.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €16.6B EUR | -9.3% | -1.6% | 81.6% | |
| Jun 2026 | $4.42B USD | +22.9% | -34.9% | 35.3% | |
| Mar 2026 | -$445.3M USD | -12.6% | — | 436.0% | |
| Mar 2026 | -$740.74M USD | -13.6% | — | 415.4% | |
| Mar 2026 | -$818.3M USD | -3.5% | — | 76.3% | |
| Sep 2026 | -$940.91M USD | -42.9% | — | 186.1% | |
| Dec 2025 | -$1.19B USD | -36.0% | — | 356.5% | |
| Mar 2026 | -$1.57B USD | -9.0% | — | 549.5% | |
| Sep 2026 | -$1.93B USD | -0.0% | — | 114.7% | |
| Sep 2026 | -$2.92B USD | -8.2% | — | 295.0% | |
| Sep 2026 | -$4.77B USD | -30.3% | — | 783.5% | |
| Peer median (excluding IOVA) | — | -10.9% | -18.2% | 271.3% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 78.23M | 231.73M | 114.89M | 115.69M | 163.08M |
| Short-term Investments | 426.18M | 240.11M | 164.98M | 208.09M | 133.9M |
| Net Receivables | 0 | 0 | 151K | 69.34M | 82.45M |
| Inventory | 0 | 0 | 10.37M | 51.52M | 51.68M |
| Other Current Assets | 0 | 7.27M | 17.46M | 12.38M | 11.58M |
| Total Current Assets | 507.96M | 479.12M | 307.85M | 457.02M | 442.69M |
| Property, Plant & Equipment (Net) | 169.92M | 178.25M | 176.55M | 164.28M | 177.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 229.26M | 282.4M | 279.32M |
| Long-term Investments | 91.59M | 0 | 66.43M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.87M | 6.62M | 270K | 6.73M | 14.15M |
| Total Non-current Assets | 269.38M | 184.87M | 472.5M | 453.41M | 470.48M |
| Total Assets | 777.33M | 663.98M | 780.35M | 910.43M | 913.17M |
| Account Payables | 27.38M | 26.6M | 33.12M | 27.51M | 22.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 4.04M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 34.59M | 50.03M | 112.16M |
| Total Current Liabilities | 89.2M | 91.49M | 110.31M | 122.34M | 138.36M |
| Long-term Debt | 1M | 1M | 1M | 1M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 17.35M | 32.32M | 31.83M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 66.47M | 72.86M | 85.43M | 77.68M | 76.23M |
| Total Liabilities | 155.67M | 164.34M | 195.74M | 200.02M | 214.59M |
| Common Stock | 7K | 8K | 11K | 13K | 17K |
| Retained Earnings | (1.17B) | (1.57B) | (2.01B) | (2.38B) | (2.78B) |
| Accumulated OCI | (601K) | (902K) | 2.53M | (1.05M) | 16.44M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 621.66M | 499.64M | 584.61M | 710.41M | 698.58M |
| Total Debt | 71.53M | 85.45M | 75.86M | 58.26M | 48.44M |
| Net Debt | (6.7M) | (146.29M) | (39.03M) | (57.43M) | (114.63M) |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.